Player FMアプリでオフラインにしPlayer FMう!
#118 - Lloyd Klickstein, M.D., Ph.D.: Rapamycin, mTOR inhibition, and the biology of aging
Manage episode 266357015 series 2432666
- His background and decision to leave academia for translational medicine [6:15];
- Translational medicine—bridging the gap between basic science and clinical medicine [10:30];
- What prompted Lloyd to focus on mTOR inhibition? [18:00];
- Defining mTOR, TORC1, and TORC2, and the consequences of inhibiting them with rapamycin [21:30];
- Dose-dependent impact of rapamycin on immune function, mTOR inhibition, and toxicity [42:15];
- Lloyd’s 2014 experiment—mTOR inhibition improves immune function in the elderly [53:00];
- Insights into autophagy, antigen presentation, and the pleiotropic benefits of a rapalog, and how it compares to fasting [1:13:00];
- Lloyd’s 2018 experiment—TORC1 inhibition enhances immune function and reduces infections in the elderly [1:18:45];
- Creation of resTORbio, subsequent studies, and takeaways about dosing, TORC2 inhibition, and tissue selectivity [1:29:00];
- Comparing the longevity effect of rapamycin, fasting, and caloric restriction [1:40:00];
- Excitement around RTB101—resTORbio’s mTOR inhibiting molecule [1:47:00];
- Identifying rapalogs selective for TORC1 [1:56:15];
- Treating depression with ketamine, an activator of mTOR [2:00:00];
- Epigenetic clocks, rapalogs, and metformin [2:03:30]; and
- More.
Learn more: https://peterattiamd.com/ Show notes page for this episode: https://peterattiamd.com/LloydKlickstein Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ Connect with Peter on Facebook | Twitter | Instagram.
345 つのエピソード
Manage episode 266357015 series 2432666
- His background and decision to leave academia for translational medicine [6:15];
- Translational medicine—bridging the gap between basic science and clinical medicine [10:30];
- What prompted Lloyd to focus on mTOR inhibition? [18:00];
- Defining mTOR, TORC1, and TORC2, and the consequences of inhibiting them with rapamycin [21:30];
- Dose-dependent impact of rapamycin on immune function, mTOR inhibition, and toxicity [42:15];
- Lloyd’s 2014 experiment—mTOR inhibition improves immune function in the elderly [53:00];
- Insights into autophagy, antigen presentation, and the pleiotropic benefits of a rapalog, and how it compares to fasting [1:13:00];
- Lloyd’s 2018 experiment—TORC1 inhibition enhances immune function and reduces infections in the elderly [1:18:45];
- Creation of resTORbio, subsequent studies, and takeaways about dosing, TORC2 inhibition, and tissue selectivity [1:29:00];
- Comparing the longevity effect of rapamycin, fasting, and caloric restriction [1:40:00];
- Excitement around RTB101—resTORbio’s mTOR inhibiting molecule [1:47:00];
- Identifying rapalogs selective for TORC1 [1:56:15];
- Treating depression with ketamine, an activator of mTOR [2:00:00];
- Epigenetic clocks, rapalogs, and metformin [2:03:30]; and
- More.
Learn more: https://peterattiamd.com/ Show notes page for this episode: https://peterattiamd.com/LloydKlickstein Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ Connect with Peter on Facebook | Twitter | Instagram.
345 つのエピソード
すべてのエピソード
×プレーヤーFMへようこそ!
Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。